Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Jaymie Estrella, PhD, Sattva S. Neelapu, MD, Richard Eric Davis, MD, Laurence Doyle, MD, Richard F Little, MD, MPH, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 3729.

https://doi.org/10.1182/blood.V118.21.3729.3729

Published: 2011

Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD

Blood (2011) 118 (21): 3718.

https://doi.org/10.1182/blood.V118.21.3718.3718

Published: 2011

Journal Articles

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

Daniela Buglio, MD, PhD, Manuela Lemoine, PhD, Sattva S. Neelapu, MD, Francisco Vega, MD, PhD, Donald Berry, Anas Younes, MD

Blood (2011) 118 (21): 4965.

https://doi.org/10.1182/blood.V118.21.4965.4965

Published: 2011

Journal Articles

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Anas Younes, MD, Francisco Hernandez, R. Gregory Bociek, MD, Yvette L. Kasamon, Peter Lee, MD, PhD, Lia Gore, MD, Daniela Buglio, MD, PhD, Amanda Copeland

Blood (2010) 116 (21): 3959.

https://doi.org/10.1182/blood.V116.21.3959.3959

Published: 2010

Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD

Blood (2010) 116 (21): 3964.

https://doi.org/10.1182/blood.V116.21.3964.3964

Published: 2010

Journal Articles

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

Enrico Derenzini, MD, Daniela Buglio, MD, PhD, Hiroshi Katayama, PhD, Yuan Ji, PhD, Subrata Sen, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2848.

https://doi.org/10.1182/blood.V116.21.2848.2848

Published: 2010

Journal Articles

The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

Adam Jona, Noor Khaskhely, MD, PhD, Daniela Buglio, MD, PhD, Jessica A. Shafer, MD, Enrico Derenzini, MD, Catherine M Bollard, MD, Arpad Illes, MD, PhD, Michael Andreef, MD, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2850.

https://doi.org/10.1182/blood.V116.21.2850.2850

Published: 2010

Journal Articles

The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

Manuela Lemoine, PhD, Daniela Buglio, MD, PhD, Adam Jona, Enrico Derenzini, MD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2851.

https://doi.org/10.1182/blood.V116.21.2851.2851

Published: 2010

Journal Articles

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Daniela Buglio, MD, PhD, Sangeetha Palakurti, PhD, Francisco Vega, PhD, Sattva S. Neelapu, Donald Berry, PhD, Yuan Ji, PhD, Kate Byth, PhD, Anas Younes, MD

Blood (2010) 116 (21): 2852.

https://doi.org/10.1182/blood.V116.21.2852.2852

Published: 2010

NARROW

The Allosteric AKT Inhibitor MK-2206 Demonstrates Potent Antiproliferative Activity in Lymphoma Cells and Synergizes with the HDAC Inhibitor Vorinostat,

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival

ENGAGE- 501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Combined Inhibition of Janus and Aurora Kinases by the Novel Small Molecule Inhibitor AZD1480 Induces Cell Death and Downregulates PD-L1 and PD-L2 Expression In Hodgkin Lymphoma

The Histone Deacetylase Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

The Pan-Deacetylase Inhibitor Panobinostat Downregulates HIF-1α and VEGF and, Synergizes with Everolimus In Hodgkin Lymphoma Cell Lines

Inhibition of Tak-1 by AZ-Tak1 Impairs NF-κB Activation, Downregulates XIAP and Activates Caspase-9 Inducing Apoptosis In Mantle Cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only